🔬 The facility is 20,000 square feet and will help Entos advance its pipeline of 20 programs.
💰 The cost of the facility has not been disclosed, but it has room for expansion.
🌎 Entos also plans to build a commercial manufacturing facility in Alberta, Canada, as part of its global manufacturing strategy.
Introduction:
Genetic medicine developer Entos Pharmaceuticals has opened a Good Manufacturing Practice (GMP) facility in Carlsbad, California. The 20,000-square-foot facility aims to support IND-enabling studies and clinical trials for Entos’ pipeline of 20 wholly owned and partnered programs. The company wants to have in-house manufacturing capabilities to ensure a reliable supply of drug substances for its candidates.
- Entos Pharmaceuticals has opened a 20,000-square-foot GMP facility in Carlsbad, CA to support IND-enabling studies and clinical trials.
- The company aims to have in-house manufacturing capabilities to ensure a reliable supply of drug substances for its pipeline.
- The facility is part of Entos’ global manufacturing strategy, with plans to build a commercial manufacturing facility in Canada.
- Entos focuses on developing genetic medicines based on its Fusogenix proteolipid vehicle (PLV) drug delivery system.
- The company’s pipeline includes a COVID-19 DNA vaccine, gene therapies for cancer, and candidates for age-related diseases and neurological disorders.
Conclusion:
Entos Pharmaceuticals has expanded its manufacturing capabilities with the opening of a GMP facility in Carlsbad, CA. By having in-house manufacturing, the company aims to ensure a reliable supply of drug substances for its broad pipeline of genetic medicines. This facility is part of Entos’ global manufacturing strategy, which also includes plans to build a commercial manufacturing facility in Canada. With a focus on its Fusogenix PLV drug delivery system, Entos is advancing a diverse pipeline of candidates for various disorders, including a COVID-19 vaccine, gene therapies for cancer, and treatments for age-related diseases and neurological disorders.
